Observational studyJournal of psychiatric practice2026
Analysis of the Use of Duloxetine in the High-dose Range (90 to 120 mg) in the Psychiatric Clinic for the Treatment of Patients With Major Depressive Disorder.
Observational study in Journal of psychiatric practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesDuloxetine is a serotonin and norepinephrine reuptake inhibitor antidepressant drug. The goal of this project was to analyze the characteristics of patients with major depressive disorder (MDD) treated with duloxetine in the high-dose range (90 to 120 mg).
methodsA retrospective, multicenter study was designed to analyze 20 indicators on the clinical use of duloxetine (90 to 120 mg) in adults with MDD who were referred to the psychiatric clinic.
resultsA total of 175 psychiatrists participated in the study and collected information on 1050 patients with a mean age of 51.3 years (62.9% women). A total of 55.4% had comorbid psychiatric conditions, with dysthymia (17.2%), generalized anxiety disorder (15%), and personality disorders (13.1%) being the most common. A total of 84.7% had nonpsychiatric conditions, including chronic pain (28.8%), fibromyalgia (22.4%), sleep disorders (20.5%), arterial hypertension (17.8%), dyslipidemia (16.3%), neuropathic pain (11.4%), and cognitive impairment (5.8%). In all, 45.3% of the sample were found to be markedly to extremely ill. A total of 84.3% had received 1 to more than 4 prior lines of therapy. The most common reason for prescribing duloxetine in the high-dose range was a lack of efficacy of previous treatment (41%) or because the patient showed only a partial response to lower doses of duloxetine (30.7%).
conclusionA greater than expected proportion of patients with advanced, marked, or severe disease, psychiatric comorbidity, sleep disorders, neuropathic pain, and cognitive impairment was observed among the subjects with MDD treated with high-dose duloxetine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.